ZHIFEI-BIOL(SZ:300122) Zhong Guo Jin Rong Xin Xi Wang·2025-08-13 07:58Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd. has achieved a significant breakthrough in the influenza vaccine sector with the launch of its quadrivalent influenza virus split vaccine, marking the first vaccination in Hefei, Anhui Province, which enhances the domestic influenza vaccine market supply and strengthens the company's capabilities in infectious disease prevention [1][3]. Group 1: Vaccine Launch and Impact - The quadrivalent influenza vaccine is designed for individuals aged 3 and above and is produced using WHO-recommended influenza virus strains, showcasing good safety profiles [5]. - The vaccine's introduction provides more options for the public, particularly benefiting high-risk groups such as infants, the elderly, pregnant women, and patients with chronic diseases, thereby improving vaccine accessibility and public health in Hefei [3][5]. Group 2: Research and Development Pipeline - Zhifei Biological has a robust pipeline of influenza vaccines, including a quadrivalent split vaccine for children and a trivalent split vaccine, both of which are in the application review stage for market approval [5]. - The company is also advancing several other vaccine candidates, including a quadrivalent split vaccine with adjuvant in clinical trials and a trivalent split vaccine that has received clinical approval [5][6]. Group 3: Innovation and Future Prospects - The development of the influenza vaccine is part of Zhifei Biological's broader commitment to innovation, with multiple vaccine candidates in various stages of development, including rabies, pneumonia, and meningitis vaccines [6]. - The company has established research and production bases in Beijing, Anhui, and Chongqing, along with an innovation incubation center, to enhance its capabilities in vaccine and biopharmaceutical development [7].